Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease

被引:25
作者
Bravo, EL [1 ]
机构
[1] Cleveland Clin Fdn, Dept Hypertens & Nephrol, Cleveland, OH 44195 USA
关键词
CONGESTIVE-HEART-FAILURE; MYOCARDIAL FIBROSIS; VASCULAR INJURY; SPIRONOLACTONE; CORTICOSTERONE; SECONDARY; RAT;
D O I
10.1007/s11906-003-0068-z
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Recent preclinical and clinical studies indicate that aldosterone, independent of angiotensin II and elevated blood pressure, may play a role in health and disease. In addition to its role in fluid and electrolyte balance and circulatory homeostasis, more recent studies have identified aldosterone as a critical mediator of vascular damage. In animal studies, aldosterone is implicated in cardiac and vascular fibrosis, renal disease, and cerebrovascular damage. These lesions are prevented by specific aldosterone receptor blockade. In clinical studies, aldosterone receptor antagonism is associated with decreased hospitalization, symptomatology, and mortality, and improvement of endothelial dysfunction in patients with chronic heart failure. A better understanding of aldosterone's actions in nonepithelial tissues should pave the way to better protection of organs at risk such as the kidneys, heart, and brain.
引用
收藏
页码:122 / 125
页数:4
相关论文
共 28 条
  • [1] EFFECTS OF ADDING SPIRONOLACTONE TO AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR IN CHRONIC CONGESTIVE-HEART-FAILURE SECONDARY TO CORONARY-ARTERY DISEASE
    BARR, CS
    LANG, CC
    HANSON, J
    ARNOTT, M
    KENNEDY, N
    STRUTHERS, AD
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (17) : 1259 - 1265
  • [2] BRAVO EL, 1988, HYPERTENSION, V11, P207
  • [3] SPIRONOLACTONE AS A NONSPECIFIC TREATMENT FOR PRIMARY ALDOSTERONISM
    BRAVO, EL
    DUSTAN, HP
    TARAZI, RC
    [J]. CIRCULATION, 1973, 48 (03) : 491 - 498
  • [4] ANTI-ALDOSTERONE TREATMENT AND THE PREVENTION OF MYOCARDIAL FIBROSIS IN PRIMARY AND SECONDARY HYPERALDOSTERONISM
    BRILLA, CG
    MATSUBARA, LS
    WEBER, KT
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1993, 25 (05) : 563 - 575
  • [5] REACTIVE AND REPARATIVE MYOCARDIAL FIBROSIS IN ARTERIAL-HYPERTENSION IN THE RAT
    BRILLA, CG
    WEBER, KT
    [J]. CARDIOVASCULAR RESEARCH, 1992, 26 (07) : 671 - 677
  • [6] BRODY MJ, 1991, HYPERTENSION S3, V18, P7
  • [7] CHARGAVA A, 2001, ENDOCRINOLOGY, V142, P1587
  • [8] Epithelial sodium channel regulated by aldosterone-induced protein sgk
    Chen, SY
    Bhargava, A
    Mastroberardino, L
    Meijer, OC
    Wang, J
    Buse, P
    Firestone, GL
    Verrey, F
    Pearce, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) : 2514 - 2519
  • [9] Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
    Farquharson, CAJ
    Struthers, AD
    [J]. CIRCULATION, 2000, 101 (06) : 594 - 597
  • [10] Medical management of aldosterone-producing adenomas
    Ghose, RP
    Hall, PM
    Bravo, EL
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (02) : 105 - +